Charlotte D Jacobs
Stanford University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Charlotte D Jacobs as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:08 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT00238628 · A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung CancerStanford University · completed · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- BEXAROTENE IN COMBINATION WITH IRESSA IN TREATMENT OF NON-SMALL CELL LUNG CANCERM01RR000070 · NCRR · STANFORD UNIVERSITY · fiscal years 2004 to 2006 · $13,343 awarded in 2006Same name and institution; not confirmed by an ID
- STANFORD UNIVERSITY PARTICIPATION IN THE NCOGU10CA025862 · NCI · STANFORD UNIVERSITY · fiscal years 1985 to 1986 · $39,152 awarded in 1986Same name and institution; not confirmed by an ID
- DAY CARE CENTER--COREP01CA034233 · NCI · STANFORD UNIVERSITY · fiscal years 1985Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:08 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.Cancer Chemother Pharmacol · 201215 citationsRCR 0.6
- Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.Anticancer Drugs · 20139 citationsRCR 0.3
- A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).Cancer Chemother Pharmacol · 20128 citationsRCR 0.2
- A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).Cancer Chemother Pharmacol · 20126 citationsRCR 0.2